Gene name:
IFNGR2 (IFNGT1) ;
Protein name:
Interferon gamma receptor 2 (IFN-gamma receptor 2;IFN-gamma-R2) ;
Alternative:
Interferon gamma transducer 1 ;Interferon gamma receptor accessory factor 1 (AF-1) ;
Organism:
Human (Homo sapiens).
General Annotation
Function:
Part of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2.
Subcellular Location:
Membrane
Single-pass type I membrane protein
Protein Attributes:
50:
MRPTLLWSLL | LLLGVFAAAA | AAPPDPLSQL | PAPQHPKIRL | YNAEQVLSWE |
100:
PVALSNSTRP | VVYQVQFKYT | DSKWFTADIM | SIGVNCTQIT | ATECDFTAAS |
150:
PSAGFPMDFN | VTLRLRAELG | ALHSAWVTMP | WFQHYRNVTV | GPPENIEVTP |
200:
GEGSLIIRFS | SPFDIADTST | AFFCYYVHYW | EKGGIQQVKG | PFRSNSISLD |
250:
NLKPSRVYCL | QVQAQLLWNK | SNIFRVGHLS | NISCYETMAD | ASTELQQVIL |
300:
ISVGTFSLLS | VLAGACFFLV | LKYRGLIKYW | FHTPPSIPLQ | IEEYLKDPTQ |
337:
PILEALDKDS | SPKDDVWDSV | SIISFPEKEQ | EDVLQTL
Vaild Sequence:
Related Databases
Uniprot:
ELISA Kit
CLIA Kit
Polyclonal Antibody
Monoclonal Antibody
Protein
FOR
Human
ELISA Kit for Human IFN-gamma receptor 2
CLIA Kit for Human IFN-gamma receptor 2
Polyclonal Antibody for Human IFN-gamma receptor 2
Monoclonal Antibody for Human IFN-gamma receptor 2
Protein for Human IFN-gamma receptor 2
R&D Technical Data
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Precision
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Recovery
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
Linearity
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
References
1.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [MRNA];VARIANT ARG-64
tissue :
Lung fibroblast .
2.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANTS ARG-58; LYS-147 AND GLU-182
3.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA];VARIANT ARG-64
tissue :
Skin .
4.
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24
5.
"Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations."
Vogt G.
,
Chapgier A.
,
Yang K.
,
Chuzhanova N.
,
Feinberg J.
,
Fieschi C.
,
Boisson-Dupuis S.
,
Alcais A.
,
Filipe-Santos O.
,
Bustamante J.
,
de Beaucoudrey L.
,
Al-Mohsen I.
,
Al-Hajjar S.
,
Al-Ghonaium A.
,
Adimi P.
,
Mirsaeidi M.
,
Khalilzadeh S.
,
Rosenzweig S.
,
de la Calle-Martin O.
,
Bauer T.R.
,
Puck J.M.
,
Ochs H.D.
,
Furthner D.
,
Engelhorn C.
,
Belohradsky B.
,
Mansouri D.
,
Holland S.M.
,
Schreiber R.D.
,
Abel L.
,
Cooper D.N.
,
Soudais C.
,
Casanova J.-L.
more...
Nat. Genet.37:692-700(2005)
[
PubMed ]
[
Europe PMC ]
[
Abstract ]
[15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s)
Cited for : VARIANTS IMD28 ASN-168 AND 222-ASN--SER-230 DEL;MUTAGENESIS OF THR-168;CHARACTERIZATION OF VARIANTS IMD28 ASN-168 AND 222-ASN--SER-230 DEL